MONTREAL, Oct. 4, 2023
/CNW/ - Valeo Pharma Inc. (TSX: VPH) (OTCQB: VPHIF) (FSE: VP2)
("Valeo" or the "Company"), a Canadian pharmaceutical
company, is pleased to announce it placed No. 151 on the 2023
Report on Business ranking of Canada's Top Growing Companies.
Canada's Top Growing Companies
ranks Canadian companies on three-year revenue growth. Valeo
placed 151st out of 425 companies that earned a spot in
this year's rankings with three-year growth of 322%.
"Valeo Pharma is proud to have been named one of Canada's fastest growing companies by the
Globe and Mail", said Steve Saviuk,
CEO. ''This ranking is a result of the dedication of all of Valeo's
employees and reflects the value that our innovative product
portfolio brings to improving healthcare for Canadian
patients".
Canada's Top Growing Companies
is an editorial ranking that was launched in 2019. It aims to bring
the accomplishments of innovative businesses in Canada to the forefront. In order to qualify
for this voluntary program; companies had to complete an in-depth
application process and fulfill requirements.
The full list of 2023 winners along with editorial coverage is
published in the October issue of Report on Business magazine. The
list is out now and online here.
"Canada's Top Growing Companies
acknowledges the drive and ingenuity displayed by Canadian
business," says Dawn Calleja, Editor
of Report on Business magazine. "This year's ranking serves as an
inspiration for future business owners."
"This year's Report on Business magazine's list of Top Growing
Companies shows how innovative ideas always rise to the top,
perhaps even more so in times of uncertainty," says Andrew Saunders, CEO of The Globe and Mail. "The
Globe and Mail congratulates this year's winners for meeting and
surpassing those economic challenges."
About The Globe and Mail
The Globe and Mail is Canada's
foremost news media company, leading the national discussion and
causing policy change through brave and independent journalism
since 1844. With our award-winning coverage of business, politics
and national affairs, The Globe and Mail newspaper reaches 6.2
million readers every week in our print or digital formats, and
Report on Business magazine reaches 2.7 million readers in print
and digital every issue. Our investment in innovative data science
means that as the world continues to change, so does The Globe. The
Globe and Mail is owned by Woodbridge, the investment arm of the Thomson
family.
About Valeo Pharma Inc.
Valeo Pharma is a fast growing Canadian pharmaceutical company
dedicated to the commercialization of innovative prescription
products in Canada with a focus on
Respiratory/Allergy, Ophthalmology and Hospital Specialty Products.
Headquartered in Kirkland, Quebec
Valeo Pharma has all the required capabilities and the full
infrastructure to register and properly manage its growing product
portfolio through all stages of commercialization. For more
information, please visit www.valeopharma.com and follow us on
LinkedIn and Twitter.
Forward Looking
Statements
This press release contains forward-looking statements about
Valeo's objectives, strategies and businesses that involve risks
and uncertainties. These statements are "forward-looking" because
they are based on our current expectations about the markets we
operate in and on various estimates and assumptions. Actual events
or results may differ materially from those anticipated in these
forward-looking statements if known or unknown risks affect our
business, or if our estimates or assumptions turn out to be
inaccurate.
SOURCE Valeo Pharma Inc.